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A New Treatment Paradigm for Selected Patients
With Multivessel Coronary Artery Disease*John D. Puskas, MD, MSC, Amit Pawale, MD, Samin K. Sharma, MDI n this issue of JACC: Cardiovascular Interventions,Ga˛sior et al. (1), from the Medical Center ofSilesia, Poland, are to be congratulated for
their landmark contribution of the ﬁrst randomized,
controlled trial of hybrid coronary revascularization
(HCR), supporting the safety and efﬁcacy of HCR in
patients with multivessel coronary artery disease
(MCVD) referred for surgical revascularization (1).
The authors cite the “limitations of standard coronary
artery bypass grafting (CABG) and unsatisfactory
long-term patency of saphenous vein grafts (SVGs)”
as the rationale for choosing to randomize surgical re-
ferrals for HCR versus CABG. They correctly note that
the excellent long-term patency of left internal mam-
mary artery (LIMA) to left anterior descending (LAD)
artery grafts, patient preference for avoiding median
sternotomy, and improving outcomes with drug-
eluting stents in non-LAD coronary arteries are addi-
tional factors that have generated increasing interest
in HCR.SEE PAGE 1277According to the guidelines of the joint American
societies on percutaneous coronary intervention (PCI)
and CABG (2), HCR is deﬁned as planned procedures
involving LIMA-to-LAD grafting and PCI of at least 1
non-LAD coronary artery. HCR can be staged (either
PCI or LIMA-LAD bypass ﬁrst and the remaining part*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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paper to disclose.second) or a single stage (both procedures performed
under a single anesthesia, typically in a hybrid oper-
ating room). The ﬁrst reported HCR was performed in
1996 (3). Although HCR was performed very infre-
quently for many years, more recently, an increasing
number of these procedures are performed by cardiac
surgeons and interventional cardiologists who func-
tion on collaborative heart teams and who have
mastered advanced techniques in minimally invasive
surgery and PCI, allowing them to safely traverse the
signiﬁcant learning curve associated with HCR.
Several previous retrospective, nonrandomized
series (4,5) have been published suggesting that HCR
can be safe and effective and is associated with less
blood use, a very low stroke rate, shortened hospital
stay, and so on. However, evidence from well-
designed prospective, randomized clinical trials has
been lacking. Hence, the present societal guideline
recommendations for HCR are not strong. According
to the 2011 American College of Cardiology/American
Heart Association guidelines for CABG and PCI, HCR
is reasonable in patients with $1 of the following
conditions: a calciﬁed proximal aorta, poor targets for
surgery that are amenable to PCI, lack of conduits for
grafting, or unfavorable LAD anatomy for percuta-
neous intervention such as chronic total occlusion
(Class IIa recommendation) (2).
The present randomized, controlled involved
study of staged hybrid procedure, performing LIMA-
to-LAD minimally invasive direct CABG (MIDCAB)
ﬁrst and PCI as a second stage after surgery. This
procedural strategy allows conﬁrmation of LIMA-to-
LAD bypass patency and revision or reintervention
if needed. Performing PCI within 36 h postoperatively
allows cessation of perioperative bleeding before
administration of high-dose dual antiplatelet therapy
necessary for PCI. Moreover, PCI to the remaining
non-LAD lesions can then safely be performed
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This trial demonstrates that HCR is safe, feasible, and
efﬁcacious in selected population of patients with
MCVD referred for surgical revascularization.
Stroke has been the Achilles heel of CABG his-
torically. In this small study, there were no strokes
in either group. Several authors have advocated a
surgical “no-touch technique,” avoiding aortic
manipulation to minimize the risk of stroke in pa-
tients undergoing surgical coronary revasculariza-
tion; the HCR strategy naturally lends itself to this
technique and thereby holds the hope of a very
small stroke risk (6).
This study has several important limitations. Most
fundamentally, it is a small, single-center feasibility
trial apparently designed without a sample-size
calculation or power analysis for either primary or
secondary endpoints. As such, all statistical conclu-
sions must be considered hypothesis generating
rather than deﬁnitive or generalizable.
Patients enrolled in the present trial had coro-
nary disease of intermediate complexity. With a
mean SYNTAX score of w23, and a mean of 4.0
signiﬁcant coronary lesions per patient, the patients
enrolled in this RCT received a mean of 2.3 stents in
the HCR group and 2.7 conduits in the CABG group.
Despite intervention of relatively high complexity,
patients in both groups had a similarly concerning
78% rate of complete revascularization. One-year
angiographic assessment of LIMA-LAD patency (ob-
tained in w85% of patients) found a 94% patency
rate in the HCR group and a 93% patency rate in the
CABG group, with 1 narrowed LIMA in the HCR
group and 5 in the CABG group. Moreover, the
proportion of grafted or stented vessels free of
stenosis/occlusion was reportedly signiﬁcantly
higher in the HCR group than in the CABG group,
despite more frequent need for percutaneous rein-
tervention in the HCR group. No explanation is
offered for these surgical patency results. The au-
thors accomplished all-arterial revascularization in
w25% of the CABG group; although this exceeds the
rate of all-arterial revascularization in either the
U.S. or European databases, it can be argued that asuitable comparator CABG group would include a
higher rate of all-arterial revascularization to be
considered state-of-the-art.
It may be more appropriate and impactful to
study the safety and efﬁcacy of HCR in patients with
less extensive, hybrid-eligible coronary anatomy
referred for either multivessel PCI or surgical coro-
nary revascularization. Any patient with proximal
LAD stenosis and signiﬁcant lesion(s) in 1 or at most
2 other non-LAD vessels could be eligible for
randomization to HCR versus multivessel PCI. Such
a trial would address selected patients in the
ambiguous zone of the SYNTAX (TAXUS Drug-
Eluting Stent Versus Coronary Artery Bypass Sur-
gery for the Treatment of Narrowed Arteries) trial
who may have better outcomes with CABG than with
PCI, but who are often treated with PCI rather than
the more invasive option of CABG via sternotomy.
HCR, by combining the lesser invasiveness of PCI to
non-LAD lesions with the durability and longevity of
minimally invasive LIMA grafting to the LAD, may
be the procedure of choice for many such patients
and may be more easily recommended by their
cardiologists.
Left main stenosis was an exclusion criterion in the
present study, despite the publication of non-
randomized series demonstrating the safety of HCR
for isolated LM stenosis (7). Indeed, HCR may be a
preferred treatment for isolated LM distal/bifurcation
stenosis in patients with limited other coronary
disease.
In conclusion, Ga˛sior et al. (1) have contributed
importantly to our evidence base supporting the
safety and efﬁcacy of HCR. We look forward to their
report of the quality of life assessment and longer
term clinical follow-up as well as the cost-
effectiveness analysis from this important trial.
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